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ABSTRACT
Purpose: To evaluate the effects of L-arginine oral supplementation in spontaneously hypertensive pregnant rats (SHR).
Methods: Thirty SHR and ten Wistar-EPM-1 virgin female rats were used in the study. Before randomization, females were
caged with males of the same strain (3:1). Pregnancy was confirmed by sperm-positive vaginal smear (Day 0).  Wistar-EPM-
1 rats served as counterpart control (C-1).  SHR rats were randomized in 4 groups (n=10): Group Control 2, non-treated rats;
Group L-Arginine treated with L-arginine 2%; Group Alpha-methyldopa treated with  Alpha-methyldopa 33mg/Kg; Group
L-Arginine+Alpha-methyldopa treated with L-arginine 2%+Alpha-methyldopa 33mg/Kg. L-arginine 2% solution was offered
ad libitum in drinking water and Alpha-methyldopa was administered by gavage twice a day during the length of pregnancy
(20 days). Blood pressure was measured by tailcuff plethysmography on days 0 and 20. Body weight was measured on
days 0, 10 and 20. Results were expressed as mean ± SD (Standard Deviation). One-Way ANOVA/Tukey (or Kruskal-
Wallis/Dunn, as appropriate) was used for group comparisons. Statistical significance was accepted as p<0.05. Results:
There was no significant weight gain in isolated L-arginine treated SHR. Mean blood pressure decreased in L-arginine-
treated SLR compared with untreated-SHR rats. Conclusion: L-arginine oral supplementation reduces blood pressure in
spontaneously hypertensive rats during pregnancy.
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RESUMO
Objetivo: Avaliar os efeitos da oferta oral de L-arginina em ratas prenhas espontaneamente hipertensivas (SHR). Métodos:
30 SHR e 10 Wistar-EPM-1 ratas virgens foram utilizadas no estudo. Antes da distribuição, as fêmeas foram acasaladas
com machos da mesma linhagem (3:1); a prenhez foi confirmada pela presença de espermatozóides no esfregaço vaginal.
As ratas Wistar-EPM-1 foram utilizadas como controles. As ratas SHR foram aleatoriamente distribuídas em 4 grupos
(n=10): Grupo Controle-2, não-tratado; Grupo L-Arginina, tratado com L-arginina; Grupo Alfa-metildopa, tratado com alfa-
metildopa; Grupo L-Arginina+Alfa-metildopa, tratado com arginina+Alfa-metildopa.  L-arginina (2%) foi oferecida ad
libitum na água de beber e a Alfa-metildopa (33 mg/Kg) foi administrada por gavagem, duas vezes ao dia, durante toda a
prenhez (20 dias). Aferição da pressão arterial (PA) foi realizada por pletismografia da cauda, nos dias 0 e 20 e dos pesos
nos dias 0-10-20. Resultados foram expressos como média±DP (Desvio Padrão). Testes estatísticos apropriados (ANOVA
unidirecional/Tukey ou Kruskal-Walli/Dunn) foram utilizados para comparações intergrupais. P<0,05 foi considerado
significante. Resultados: Não houve ganho de peso significante nas ratas tratadas com L-arginina. A PA média diminuiu no
Grupo L-Arginina comparado ao Grupo Controle-2. Conclusão: A oferta oral de L-arginina reduz a PA em ratas SBP durante
a prenhez.
Descritores: Arginina. Prenhez. Animais de Cepas não Consangüíneas. Ratos.
Introduction
Hypertensive diseases are known to occur during
pregnancy. Moderate hypertension tends to occur at the
end of the pregnancy and does not represent a serious
harass to life. However, severe hypertension or preeclampsia
do represent a serious threat to the life of pregnant women1.
Spontaneous hypertensive rats (SHR) are a genetic model
of hypertension widely used in medical research because
of the features they share with idiopathic hypertension in
humans2. Experimental models utilizing SHR have been used
to study the effects of different drugs in pregnant rats3, 4.
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However, the behavior of blood pressure during pregnancy
has been a matter of controversy in the literature in this
animal model. Thus, no effects of pregnancy on pressure
levels5, 6 or any fall in pressure level during the last days of
pregnancy have been reported 7-11. Methyldopa is one of
the most early and the most often used drug in pregnancy-
induced hypertension. It works by relaxing the blood vessels
so that blood can flow more easily through the body12.
Recent studies have demonstrated that perinatal
supplementation of nitric oxide (NO) substrate results in
persistent reduction of systolic blood pressure in SHR4. L-
Arginine is a precursor of polyamine, nitric oxide, creatine,
and agmatine (guanidine, decarboxylated arginine), and is
essential for the differentiation and proliferation of blood
cells, although the precise biological role of L-arginine is
unclear13.  As NO substrates given during pregnancy are
able to induce a persistent reduction in systolic blood
pressure (SBP) in SHR4, oral supplementation of L-arginine
to hypertensive pregnant rats could be beneficial in
reducing SBP in these animals. Hence, this study was aimed
at studying the effects of L-arginine oral supplements in
pregnant spontaneously hypertensive rats.
Methods
Thirty spontaneously hypertensive rats (SHR) and ten
Wistar-EPM-1 virgin female rats (150-200 g, average age 90
days) obtained from the UNIFESP small animal facility, were
used in this study. All rat procedures and handling were in
compliance with the Federal University of São Paulo ethical
guidelines for handling and care of experimental animals
and the Council for International Organization of Medical
Sciences (CIOMS) ethical code for animal experimentation14.
All animals were of the same breed and were raised in
controlled environment for research use only.  The animals
were housed five per cage in a room with temperature
maintained at 22°C ± 1°C and with a 12-hour-light/12-hour-
dark cycle. All animals had free access to food and water
throughout the study. For breeding, females were caged
with males of the same strain (ratio 3:1), and vaginal smears
were checked each morning for the presence of spermatozoa.
Pregnancy was confirmed by sperm-positive vaginal smear
(Day 0). Subsequently, SHR rats were randomized in 4 groups
(n=10): Group Control 2 (SHR_C2), consisting of 10 non-
treated rats; Group L-Arginine (SHR_Arg), consisting of
10 rats treated with L-arginine 2% solution offered ad libitum
in drinking water during the length of pregnancy (20 days);
Group Alpha-methyldopa (SHR_MD) consisting of 10 rats
treated with  Alpha-methyldopa, 33mg/Kg dissolved in
drinking water 2.0ml  and administered by gavage twice a
day (7 and 19 h); Group L-Arginine+Alpha-methyldopa
(SHR_A+MD) consisting of 10 rats treated with  L-arginine
2% solution offered ad libitum in drinking water and Alpha-
methyldopa administered by gavage twice a day (7 and 19
h). Wistar-EPM-1 rats (Group Control 1 – W-EPM1_C1)
served as non-hypertensive counterpart control.
Blood pressure and body weight measurement
Systolic blood pressure was measured by tailcuff
plethysmography on days 0 and 20. Each blood pressure
value reported was the mean of five determinations that
were taken during the same session. A level of 150 mmHg or
higher was considered to be hypertension2. Body weight
was evaluated on days 0, 10, and 20 of pregnancy.
Statistical analysis
Results were expressed as mean ± SD (Standard
Deviation). One-Way ANOVA/Tukey (or Kruskal-Wallis/
Dunn, as appropriate) was used for group comparisons.
Statistical significance was accepted as p<0.05.
Results
Blood pressure
Figures 1-3 depict rat’s systolic blood pressure (SBP),
diastolic blood pressure (DBP) and mean blood pressure
(MBP) profiles, respectively.
FIGURE 1 - Rats systolic blood pressure (SBP) profile during
pregnancy. SBP values decreased significantly
in Day 20 compared with Day 0 in all groups
(p<0.001) Levels were similar in treated and
untreated rats.
FIGURE 2 - Rats diastolic blood pressure (DBP) profile
during pregnancy. DBP values decreased
significantly in Day 20 compared with Day 0 in
all groups (p<0.001), except C2.
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Weight
Figure 4 depicts weight variations during pregnancy.
were taken during the same session. Mean blood pressure
in C2 (non-treated SHR) was 178±17 and 118±24 in Day 0
and 156±35 and 98±19 in Day 20, respectively. The apparent
drop in mean blood pressure (MBP) values during
pregnancy lacked statistical significance in groups Control
1, Control 2 and L-Arginine while a significant Mean blood
pressure drop occurred in rats treated with methyldopa
(178±14 versus 129±38, p<0.01) and L-Arginine+Alpha-
methyldopa ( 192±19 versus 137±26, p<0.001). Blood pressure
levels are known to decrease during pregnancy in rats. There
is no clear explanation for this event and a number of
hypothesis have been raised, such as the number of
fetuses19-20, the angiotensin-renin system effect19, 21-22  and
endothelium-derived relaxing factor activity23. SBP values
were 34% higher in Group Control 2 rats compared with
Group Control 1 (p<0.001); Also, SBP in Alpha-methyldopa
(34%) and L-Arginine+Alpha-methyldopa (39%) groups
were higher compared with Group Control 1 (p<0.001). No
significant differences occurred when comparing mean SBP
levels in Group L-Arginine and Group Control 1 rats (Fig.
1). Just handling the rats could cause an increase in blood
pressure, as SHR strain shows an exaggerated sympathetic
response when submitted to stress24-26.
Group Control 1 (non-hypertensive Wistar EPM -1 rats)
and Group L-Arginine rats presented similar (no significant
difference) systolic and diastolic blood pressure levels at the
beginning (Day 0) and the end (Day 20) of pregnancy (Fig. 1-
2). Decreased mean blood pressure (MBP) levels (p<0.001)
were found when comparing L-arginine treated SLR with
untreated SHR groups in Day 20 (p<0.001) of pregnancy (Fig.
3). The sympathetic antagonist methyldopa is the first-choice
hypotensive agent in the treatment of pregnancy-induced
hypertension. Podjarny et al. 27 studied the effects of
methyldopa (400 mg/kg/day) and L-arginine (260 mg/kg/day)
in forty pregnant Wistar rats pretreated with L-NAME (Nitro
L-arginine methyl ester, NO synthase inhibitor, 9-10 mg/kg/
day) from mid-pregnancy (day 11) through to term and
concluded that both methyldopa and L-arginine normalized
SBP. Methyldopa or methyldopa+L-arginine treatments during
SHR pregnancy failed to provide significant reduction in MBP
in the present experiment. This result could be dose-related.
Considering that a rat ingests approximately 8-11 ml of drinking
water/100g body weight/day28 it is possible to estimate the
amount of L-arginine ingested per each animal. As L-arginine
was offered in drinking water (2% solution, 1ml = 20mg
arginine) the average rat (200g) ingested approximately 16-
22ml of water containing 320-440mg (1600 – 2200 mg/Kg/day)
of L-arginine. Therefore the dose of L-arginine given to L-
Arginine and L-Arginine+Alpha-methyldopa treated rats was
6-8 fold greater than that used by other researchers.27 Further
studies using L-arginine in different concentrations may clarify
this issue. On the other hand, the dose of methydopa used by
Podjarny et al.27 was 8- fold greater than the dose employed in
the present experiment where rats received methyldopa 66 mg/
kg/day. It is possible that the small dose used in this study
was not adequate to provide effective blood pressure reduction
in this model.
The greatest weight gain occurred in C1 rats when
comparing mean weight of all groups was observed that. SHR
treated groups (L-Arginine, Alpha-methyldopa, and L-
Arginine+Alpha-methyldopa) mean weights were not different
FIGURE 3 - Rats mean blood pressure (MBP) profile during
pregnancy. DBP values decreased significantly
in Day 20 compared with Day 0 in all groups
(p<0.001), except C2.
FIGURE 4 - Rats weight profile during pregnancy. There
was a significant weight gain during pregnancy
(from day 0 to day 20) in all groups. However,
there were no significant differences among
treated and untreated groups.
Discussion
Behavior of blood pressure during pregnancy is
controversial in rat experimental models. Some data show
no effect of pregnancy on blood pressure in the SHR
strain15-16 whereas others show a significant fall in blood
pressure in the same strain17-19. Peracoli et al.3 found a
significant reduction in blood pressure levels in pregnant
SHR groups. Blood pressure fall was dependent on the
frequency at which blood pressure was measured,
suggesting that stress can influence the behavior of blood
pressure in experimental animals. In that study, blood
pressure was measured in 9 instances. In the present study
blood pressure was measured in two occasions (beginning
–Day 0 and end of pregnancy – Day 20). Each blood pressure
value reported was the mean of five determinations that
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compared with Control 2 (untreated SHR) rats. L-arginine
treatment did not alter significantly the weight gain in L-
Arginine treated rats (Fig. 4).
Conclusion
L-arginine supplementation does not enhance weight gain
in pregnant spontaneously hypertensive rats. It is hypothesized
that L-arginine oral supplementation may reduce mean blood
pressure in spontaneously hypertensive rats.
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